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introduction: The Union for International Cancer Control–American Joint Committee on 
Cancer TNM staging system for glottic squamous cell carcinoma (SCC) includes different 
types of lesions defined by the involvement of specific subsites in each T category. Our 
study aims to identify different subcategories according to tumor local extension and 
determine oncologic outcomes after treatment by transoral laser microsurgery (TLM) alone.
Methods: We retrospectively evaluated 410 patients affected by previously untreated 
pT1-pT3 glottic SCC treated by TLM alone from January 2005 to December 2015 at the 
Departments of Otorhinolaryngology—Head and Neck Surgery, Universities of Genoa 
and Brescia, Italy. All patients had at least 2  years of follow-up. Clinical, radiological, 
surgical, and histopathological data were reviewed and tumors divided into six subcate-
gories: I, pT1a not involving the anterior commissure (AC); II, pT1b involving the AC; 
III, pT2 extending superficially to the supraglottis or the subglottis; IV, pT2 infiltrating 
the vocal muscle; V, pT3 involving the anterior paraglottic space; VI, pT2 or pT3 with 
vertical extension across the AC with/without involvement of the pre-epiglottic space. 
Recurrence-free survival (RFS), local control with laser alone (LCL), and organ preserva-
tion (OP) were defined as the primary oncologic outcomes.
results: The 2, 5, and 10-year RFS for the entire series were 85.7, 80.3, and 73.8%, 
LCL rates 93.8, 92.1, and 89.6%, and OP rates 96.8, 95.9, and 93.5%, respectively. 
However, when comparing the rates of RFS, LCL, and OP for each subcategory, 
important differences emerged. In particular, subcategories V and VI showed a signifi-
cantly increased risk of local recurrence [hazard ratio (HR) = 9.2 and 13.3, respectively]. 
These subcategories also had a significantly reduced probability to achieve LCL (HR: 
73.6 and 93.5, respectively) and OP (HR: 6.4 and 8.1, respectively).
conclusion: The present classification in subcategories allows introducing the concept 
of a three-dimensional map of isoprognostic zones in glottic SCC treated by TLM alone 
as a useful tool in its management by a multidisciplinary tumor board.
Keywords: transoral laser microsurgery, laryngeal cancer, glottic cancer, carbon dioxide laser, prognosis, 
oncologic outcomes
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inTrODUcTiOn
Modern literature is replete of clear-cut evidence in favor of 
the good oncologic and functional outcomes of transoral laser 
microsurgery (TLM) for treatment of T1–T2 and selected T3 glot-
tic squamous cell carcinomas (SCC) (1–14). Accurate and tailored 
patient selection, application of a multi-step diagnostic work-up 
based on pre- and intraoperative endoscopy, surgically oriented 
imaging assessment by dedicated head and neck radiologists, use 
of a state-of-the-art laser technology, and knowledge of pathways 
of spreading and recurrence have allowed clinicians to obtain, 
in large-volume oncologic centers, outstanding and reproduc-
ible results. However, even the 8th Edition of the TNM staging 
system (15) is definitively too simplistic to precisely define the 
different possible extensions of glottic tumors (especially when 
dealing with T2 and T3 lesions), thus limiting a proper patient 
and interdisciplinary counseling. In fact, these T categories may 
differ according to the involvement of various glottic subsites, 
superficial spreading to the supraglottis or subglottis, deep 
extension toward visceral compartments [paraglottic (PGS) and 
pre-epiglottic spaces (PES)], vocal cord/arytenoid mobility, and 
infiltration of the cartilaginous framework.
Too frequently, even in well-structured multidisciplinary boards, 
the “T–N categories criterion” is the only one used to define a lesion 
and, therefore, to choose among the most appropriate therapeutic 
strategies. Indeed, our experience (4, 5, 9), as well as those of others 
(6–8), clearly shows that profound differences exist among tumors 
usually grouped together under the same T category but, in reality, 
presenting very different surgical challenges, oncological prognosis, 
and possible functional sequelae. The process of subdividing each 
T category in a number of more homogeneous subgroup of lesions 
should help in communicating and sharing therapeutic outcomes 
to be achieved in every single case scenario, thus making a custom 
tailored approach for evaluation and treatment of a specific tumor 
more feasible.
The present study introduces a new conceptual tool that we 
have defined “three-dimensional (3D) map of isoprognostic 
zones,” which allows for the definition, for each therapeutic 
strategy, of the oncologic outcomes that are reasonably obtainable 
for each specific T subcategory, more precisely than previously 
obtained by the simple use of TNM stratification alone. Herein, 
we embraced such a subcategorization to depict an isoprognostic 
zones map related to the use of TLM as a unimodal treatment 
strategy for management of early-intermediate glottic SCCs. 
However, the same process could be extended to other T and N 
categories, laryngeal subsites, or head and neck sites, as well as to 
other surgical and non-surgical treatment modalities, taken alone 
or in various combinations.
The aim of the present study is to retrospectively stratify in 6 
subcategories, defining an equal number of isoprognostic zones, 
a cohort of 410 T1, T2, and selected T3 glottic SCCs according to 
location and extension, describe different patterns of growth and 
possible pathways of recurrence, and define the role and limits of 
TLM as a single treatment modality in terms of recurrence-free 
survival (RFS), local control with laser alone (LCL), and organ 
preservation (OP) rates for each subcategory.
MaTerials anD MeThODs
We retrospectively evaluated 410 patients (371 males and 39 
females) affected by previously untreated T1–T3 glottic SCC 
managed by TLM alone from January 2005 to December 2015 
at the Departments of Otorhinolaryngology—Head and Neck 
Surgery, Universities of Genoa and Brescia, Italy. Patients age 
ranged from 31 to 94  years (median, 68), and all had at least 
2  years of follow-up (range, 24–120  months; median, 72). 
Inclusion criteria were glottic pT1, pT2, and selected pT3 SCC 
with evidence of limited anterior PGS and/or PES involvement 
and adequate laryngeal exposure preoperatively assessed by 
the Laryngoscore (16). Patients affected by T3 glottic SCC with 
minimal laryngeal framework invasion or arytenoid fixation 
due to posterior PGS involvement and those previously treated 
elsewhere with TLM, radiotherapy (RT), chemoradiotherapy 
(CRT), or open partial horizontal laryngectomies (OPHL) were 
excluded from the present study.
Preoperative flexible videolaryngoscopy assessed superficial 
tumor margins under white light (WL) and narrow band imag-
ing (NBI, Olympus Medical System Corporation, Tokyo, Japan). 
Deep neoplastic extension was evaluated using contrast enhanced 
imaging [computed tomography or magnetic resonance (MR)] 
performed by dedicated head and neck radiologists. Neck ultra-
sound with or without fine needle aspiration cytology was rou-
tinely performed in lesions with significant supraglottic extension 
or those defined as glottic cT3. Intraoperative rigid endoscopy 
with 0°, 30°, and 70° telescopes under WL and NBI was accom-
plished during microlaryngoscopy to obtain better definition of 
superficial surgical margins (17). All patients underwent TLM 
using previously described surgical techniques and instrumenta-
tion (9, 16). Patients with clinically negative neck nodes received 
purely local treatment by TLM. Four patients with clinically 
positive neck disease underwent unilateral selective (levels II–V) 
neck dissection. Transoral re-excision was accomplished in case 
of deep or more than one superficial positive margins. We also 
excluded patients who received adjuvant treatments (RT and/or 
CRT) due to the presence of persistent tumor after re-excision, 
perineural invasion, angioembolization, multiple positive lymph 
nodes, or extracapsular spread. We retrospectively reviewed 
clinical, radiological, surgical, and histopathological data, and 
divided tumors accordingly into six subcategories: I, pT1a not 
involving the anterior commissure (AC); II, pT1b involving 
the AC or both vocal folds; III, pT2 extending superficially to 
the supraglottis or the subglottis; IV, pT2 infiltrating the vocal 
muscle (VM); V, pT3 involving the anterior PGS; VI, pT2 or 
pT3 with trans-AC extension with or without involvement of 
the PES.
Abbreviations: 3D, three-dimensional; UICC, Union for International Cancer 
Control; AJCC, American Joint Committee on Cancer; SCC, squamous cell 
carcinoma; TLM, transoral laser microsurgery; AC, anterior commissure; RFS, 
recurrence-free survival; LCL, local control with laser alone; OP, organ preserva-
tion; HR, hazard ratio; PGS, paraglottic space; PES, pre-epiglottic space; RT, radio-
therapy; CRT, chemoradiotherapy; OPHL, open partial horizontal laryngectomy; 
WL, white light; NBI, narrow band imaging; CT, computed tomography; MR, 
magnetic resonance.
Table 1 | Recurrence-free survival (RFS), local control with laser alone (LCL), and organ preservation (OP) at 2, 5, and 10 years for each subcategory.
rFs lcl OP
2 years (%) 5 years (%) 10 years (%) 2 years (%) 5 years (%) 10 years (%) 2 years (%) 5 years (%) 10 years (%)
Overall series 85.7 80.3 73.8 93.8 92.1 89.6 96.8 95.9 93.5
Subcategory I 95.1 90.7 90.7 100 99.1 99.1 100 100 100
Subcategory II 82.1 68.0 – 100 89.4 74.5 97.6 90.1 77.2
Subcategory III 85.5 81.6 68.0 90.7 90.7 90.7 95.1 95.1 95.1
Subcategory IV 77.1 68.1 68.1 86.1 86.1 86.1 94.4 94.4 94.4
Subcategory V 60.7 60.7 – 71.9 71.9 – 89.9 89.9 –
Subcategory VI 48.6 – – 66.7 – – 75 – –
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All tumors were restaged according to the eighth edition of 
the Union for International Cancer Control—American Joint 
Committee on Cancer TNM staging system (15). At the time of 
diagnosis, the cT categories were as follows: 284 cT1a-b, 84 cT2, 
and 42 cT3. The pT stage and the ensuing division in subcat-
egories were 211 pT1a (subcategory I); 61 pT1b (subcategory II); 
45 pT2 (subcategory III); 41 pT2 (subcategory IV); 40 pT3 (sub-
category V); and 12 pT2-pT3 (subcategory VI).
No approval from the Ethics Committee for this study was 
deemed necessary at our Institutions after a formal request to 
the appropriate parties. Each patient signed an informed consent 
for treatment of personal data for scientific purposes before 
enrollment.
statistical analysis
Statistical analysis was carried out using STATA 13 software 
(StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX, USA: StataCorp LP). 2-, 5-, and 10-year RFS, LCL, 
and OP rates were evaluated by the Kaplan–Meier product limit 
estimate. Subcategories were first individually compared among 
each other by the log-rang test (I vs. II, II vs. III, III vs. IV, IV vs. 
V, and V vs. VI) to identify major differences in terms of RFS, 
LCL, and OP. Subcategory I has been considered the reference 
point [hazard ratio (HR) =  1] when evaluating RFS and LCL. 
Conversely, the reference point for OP was subcategory II, due 
to the lack of events (total laryngectomies) in subcategory I. 
Furthermore, a Cox proportional hazard regression model was 
employed to quantify the stratification potential of subcategories 
(considered as a categorical variable) and to obtain the related HR 
for RFS, LCL, and OP. No further variable was included in the 
regression model, since a different distribution of risk factors was 
not considered as a confounding element, but as one of the bases 
for the subcategory stratification itself. Comparisons between 
survival curves were carried out using the log-rank test. The final 
time-point for RFS was the date of the first recurrence (patients 
who died without any recurrence were considered as censored). 
The final time-point for LCL was the date of any further open or 
non-surgical treatment for relapse. The final time-point for OP 
was the date of total laryngectomy (patients who died without a 
previous total laryngectomy were considered as censored).
resUlTs
Fifty-nine (14.4%) patients had recurrences. Forty-nine had 
a local recurrence: 13 in subcategory I (6% of patients in such 
subcategory), 11 in subcategory II (18%), 7 in subcategory III 
(15%), 6 in subcategory IV (15%), 8 in subcategory V (20%), and 4 
in subcategory VI (33%). Nine patients experienced loco-regional 
recurrence: 1 in subcategory III (2%), 3 in subcategory IV (7%), 3 
in subcategory V (8%), and 2 in subcategory VI (17%). Only one 
patient in subcategory V (2%) had an exclusively regional recur-
rence. Salvage treatment was represented by TLM in 40 patients, 
OPHL with uni- or bilateral selective neck dissection in 6, total 
laryngectomy with uni- or bilateral neck dissection in 13 (4 of 
them followed by CRT), RT alone in 1, and chemotherapy alone 
in the only patient with neck failure. One patient received best 
supportive care due to refusal of any further treatment. At the last 
follow-up (December 2017), 57 patients had died: 8 for disease 
progression, and 49 for other causes. Four patients were alive 
with disease, while in the remaining 349 there was no evidence 
of disease.
2-, 5-, and 10-year RFS rates for the entire series were 85.7, 
80.3, and 73.8%, LCL rates were 93.8, 92.1, and 89.6%, and OP 
rates were 96.8, 95.9, and 93.5%, respectively. RFS, LCL, and OP 
rates according to each pT subcategory are detailed in Table 1 
and Figures 1–3. Progressively comparing the estimates of the 
hazard functions of each subcategory with the following one, we 
evidenced a significant difference at the log-rank test between 
subcategory I and II (p = 0.004), as well as IV and V (p = 0.050) 
when considering LCL. The significant difference between sub-
category I and II was also confirmed when considering RFS and 
OP (both p < 0.001).
In the Cox proportional hazards regression analysis, according 
to our patient stratification, subcategories V and VI showed an 
approximately 10-fold increase in the risk of local recurrence, with 
an hazard ratio (HR) of 9.2 and 13.3, respectively (p < 0.001). In 
addition, the same subcategories had a greatly reduced probability 
to achieve LCL (HR = 73.6 and 93.5, respectively; p < 0.001) and 
OP (HR = 6.4 and 8.1, respectively; p < 0.01). HRs concerning 
RFS, LCL, and OP for each subcategory are detailed in Table 2.
Three-dimensional maps of the isoprognostic zones for glottic 
SCCs treated by TLM alone are depicted in Figures 4–6.
DiscUssiOn
The introduction of a novel conceptual tool such as the pre-
sent that we defined “3D map of isoprognostic zones” tries to 
overcome, in our opinion, one of the most limiting factors in 
the contemporary literature concerning TLM for laryngeal 
SCC. In fact, oncologic outcomes of such a technique (as well 
FigUre 3 | Organ preservation Kaplan–Meier curves for each subcategory.
FigUre 2 | Local control with laser alone Kaplan–Meier curves for each 
subcategory.
FigUre 1 | Recurrence-free survival Kaplan–Meier curves for  
each subcategory.
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as those of many other surgical and non-surgical therapeutic 
options) are frequently reported on the simple basis of T cate-
gory, if not stage, placing a number of different lesions such as 
T1a, T1b, T2, and limited T3 under the same umbrella term 
of “early-intermediate” tumors. The ensuing overall outcomes 
may, therefore, seem quite encouraging even though, in reality, 
a much more differentiated scenario can be described when 
one specifically peruses the T category and, especially, applies 
more detailed subcategorization, as herein reported, that is able 
to consider specific issues. Such an approach directly derives 
from the daily use of an intraoperative microscopic view of 
such lesions, coupled with systematic application of modern 
biologic endoscopy techniques, and high-resolution radiologic 
imaging. All these tools are more articulated and time-con-
suming but, nonetheless, provide a comprehensive description 
of the different possible pathways of spread of glottic SCCs. In 
fact, superficial as well as deep progression of the lesion may 
harbor different challenges in terms of local control and OP. 
In particular, the present data confirm those already published 
by our group (5, 9, 18, 19) and together form the basis of the 
conceptualization attempted by the 3D map of isoprognostic 
zones herein described.
Our results confirm both the outstanding outcomes for the 
entire cohort in terms of RFS, LCL, and OP rates obtained by 
TLM alone and the need to analyze each subcategory to better 
highlight the real value of a treatment in each isoprognostic 
zone. Indeed, the present survival curves are effectively strati-
fied according to our proposal of subcategorization. The HR 
for RFS was 4.5, 9.2, and 13.3 times significantly higher in 
subcategories IV, V, and VI, respectively, thus emphasizing that 
the vertical extension across the AC with/without involvement 
of the PES should be considered as a real weakness for the TLM 
approach. Such a crucial issue is also confirmed by the reduced 
LCL and the higher need for salvage total laryngectomy in 
subcategory VI compared with other isoprognostic zones of 
the 3D map.
In our opinion, subcategory VI has the worst outcome in the 
present series since transglottic SCCs tend to spread from the PES 
upwards into the supraglottis and hence outside the larynx due 
to the absence of a significant anatomical barrier in this area, or 
directly through the crico-thyroid membrane at the subglottic 
level. Moreover, the tangential transoral microscopic visualiza-
tion of the supra- and subcommissural areas may further penalize 
adequate surgical treatment of tumors deeply involving these 
visceral compartments.
When sequentially comparing the single subcategories, it is 
possible to observe a significant shift in LCL from subcategory 
I to II–III, as well as from IV to V–VI. This may be seen as the 
passage from a superficially confined neoplasm (subcategory I) 
to a superficially spreading tumor (subcategories II–III), finally 
shifting to a deeply infiltrating lesion involving the laryngeal 
visceral spaces (subcategories V–VI).
Still, our results, in line with the literature, highlight how 
patients in the IV subcategory have a worse outcome compared 
to the III subcategory, even if both belong to the pT2 category, 
while those included in subcategory V for deep extension to the 
anterior PGS (limited pT3 lying in front of a plane tangential to 
FigUre 5 | Three-dimensional map of the isoprognostic zones I, II, III,  
and VI, view from inside.
FigUre 4 | Three-dimensional map of the isoprognostic zones I, II, III,  
and VI, view from above.
Table 2 | Cox analysis between subcategories of recurrence-free survival (RFS), local control with laser alone (LCL), and organ preservation (OP).
rFs lcl OP
hazard ratio (hr) 95% ci p-Value hr 95% ci p-Value hr 95% ci p-Value
Subcategory I 1.0 – – 1.0 – – – – –
Subcategory II 4.0 1.86–8.68 <0.001 11.4 1.18–109.40 0.035 1.0 – –
Subcategory III 3.1 1.28–7.50 0.012 18.8 2.11–168.50 0.009 1.7 0.37–7.41 0.508
Subcategory IV 4.5 1.98–10.33 <0.001 28.2 3.29–241.09 0.002 2.5 0.59–10.31 0.218
Subcategory V 9.2 4.45–19.33 <0.001 73.6 9.55–566.86 <0.001 6.4 1.80–22.91 0.004
Subcategory VI 13.3 5.01–35.27 <0.001 93.5 10.41–840.35 <0.001 8.1 1.80–36.18 0.006
FigUre 6 | (a) Coronal view of the right hemilarynx, anterior half (E, 
epiglottis; FVC, false vocal cord; VL, vocal ligament; VM, vocal muscle;  
PGS, anterior paraglottic space; T, thyroid cartilage; C, cricoid) and  
(b) three-dimensional map of the isoprognostic zones I, III, IV, and V,  
coronal view of the right hemilarynx, anterior half.
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the arytenoid vocal process and perpendicular to the ipsilateral 
thyroid lamina) have comparable outcomes with other traditional 
therapeutic options (20–22).
In light of this, subcategories IV, V, and VI represent the 
highest-risk group of patients to be managed by TLM alone. 
Thus, as already demonstrated in previous reports (23–25), they 
merit planned radiological examination (better with MR) even in 
the absence of clinical and endoscopic doubts during follow-up, 
due to their well-known propensity to recur submucosally.
In conclusion, we can assume that the propensity to use the 
term “early-intermediate stage” to describe a wide spectrum of 
diseases ranging from lesions limited to one vocal cord to those 
with a trans-AC extension as well VM infiltration or invasion 
of the anterior PGS and/or PES, may risk erroneous inclusion 
in a given prognostic category, with subsequent application of 
suboptimal treatment strategies (26–28). Ideal oncological and 
functional outcomes require accurate and comprehensive pre- 
and intraoperative diagnostic work-up, specialized skills, and 
expertise. Poor judgment will increase the risk of recurrence or 
the need for multimodal treatments (with associated increased 
6Piazza et al. Isoprognostic Zones Map in Glottic Cancer
Frontiers in Oncology | www.frontiersin.org May 2018 | Volume 8 | Article 175
toxicity and sequelae) to achieve disease control and functional 
preservation.
We must not forget, however, that the isoprognostic zones 
presented herein are strictly related and influenced by the spe-
cific therapeutic approach chosen, i.e., in the present series, by 
TLM. However, this should not limit their application to other 
treatment modalities and, even more interestingly, could fuel a 
stimulating comparison between them, especially in the context 
of a multidisciplinary tumor board. Our ideal target in the future 
would be, therefore, to be able to precisely choose, for each lesion 
in a given patient, the most adequate therapeutic approach, in 
order to ensure the highest oncological success with the lowest 
impact in terms of morbidity and costs.
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